Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucine Vuitton

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Journal of Crohn'S & Colitis|May 14, 2024
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF AgentMathurin Fumery, Mélanie Serrero, Guillaume Bouguen, et al.
Journal of Crohn'S & Colitis|August 29, 2024
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel DiseaseDavid Laharie, Lucine Vuitton, Arnaud Bourreille, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 26, 2020
Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's diseaseJulienne Grillot, Christelle D'Engremont, Anne-Laure Parmentier, et al.
Frontiers in Oncology|June 14, 2021
Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal AdenocarcinomaChristelle d'Engremont, Julienne Grillot, Julie Raillat, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2025
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS studyAnthony Buisson, Mélanie Serrero, Romain Altwegg, et al.
The American Journal of Gastroenterology|June 29, 2021
Evaluating the Risk of Irreversible Intestinal Necrosis Among Critically Ill Patients With Nonocclusive Mesenteric IschemiaPaul Calame, Hadrien Winiszewski, Alexandre Doussot, et al.
The Journal of Dermatological Treatment|September 15, 2015
Observational case series on adalimumab-induced paradoxical hidradenitis suppurativaMarine Delobeau, Ahlam Abdou, Eve Puzenat, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2026
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID StudyNicolas Richard, Philippe Seksik, Romain Altwegg, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Journal of Crohn'S & Colitis|May 14, 2024
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF AgentMathurin Fumery, Mélanie Serrero, Guillaume Bouguen, et al.
Journal of Crohn'S & Colitis|August 29, 2024
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel DiseaseDavid Laharie, Lucine Vuitton, Arnaud Bourreille, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 26, 2020
Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's diseaseJulienne Grillot, Christelle D'Engremont, Anne-Laure Parmentier, et al.
Frontiers in Oncology|June 14, 2021
Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal AdenocarcinomaChristelle d'Engremont, Julienne Grillot, Julie Raillat, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2025
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS studyAnthony Buisson, Mélanie Serrero, Romain Altwegg, et al.
The American Journal of Gastroenterology|June 29, 2021
Evaluating the Risk of Irreversible Intestinal Necrosis Among Critically Ill Patients With Nonocclusive Mesenteric IschemiaPaul Calame, Hadrien Winiszewski, Alexandre Doussot, et al.
The Journal of Dermatological Treatment|September 15, 2015
Observational case series on adalimumab-induced paradoxical hidradenitis suppurativaMarine Delobeau, Ahlam Abdou, Eve Puzenat, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2026
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID StudyNicolas Richard, Philippe Seksik, Romain Altwegg, et al.
Pageof 13